These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15293138)

  • 1. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
    Takaki S; Tsubota A; Hosaka T; Akuta N; Someya T; Kobayashi M; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Jul; 39(7):668-73. PubMed ID: 15293138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors contributing to ribavirin-induced anemia.
    Nomura H; Tanimoto H; Kajiwara E; Shimono J; Maruyama T; Yamashita N; Nagano M; Higashi M; Mukai T; Matsui Y; Hayashi J; Kashiwagi S; Ishibashi H
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1312-7. PubMed ID: 15482540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    J Gastroenterol; 2004 Nov; 39(11):1090-4. PubMed ID: 15580403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
    Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R
    J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.
    Hu CC; Weng CH; Lin CL; Tien HC; Kuo YL; Chien CH; Yen CL; Lin CY; Chien RN
    Ren Fail; 2012; 34(4):429-34. PubMed ID: 22264026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C.
    Oze T; Hiramatsu N; Kurashige N; Tsuda N; Yakushijin T; Kanto T; Takehara T; Kasahara A; Kato M; Yoshihara H; Katayama K; Kubota S; Hijioka T; Ishibashi K; Oshita M; Hagiwara H; Haruna Y; Mita E; Tamura S; Hayashi N
    J Gastroenterol; 2006 Sep; 41(9):862-72. PubMed ID: 17048050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
    Balan V; Schwartz D; Wu GY; Muir AJ; Ghalib R; Jackson J; Keeffe EB; Rossaro L; Burnett A; Goon BL; Bowers PJ; Leitz GJ;
    Am J Gastroenterol; 2005 Feb; 100(2):299-307. PubMed ID: 15667486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.
    Hiramatsu N; Kurosaki M; Sakamoto N; Iwasaki M; Sakamoto M; Suzuki Y; Sugauchi F; Tamori A; Kakinnuma S; Matsuura K; Izumi N
    J Gastroenterol; 2011 Sep; 46(9):1111-9. PubMed ID: 21681410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients?
    Morsy KH; Zaghloul A; Mahmoud M
    Turk J Gastroenterol; 2016 Jan; 27(1):55-61. PubMed ID: 26674982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
    Itoh Y; Okanoue T
    J Gastroenterol; 2004 Jul; 39(7):704-5. PubMed ID: 15293148
    [No Abstract]   [Full Text] [Related]  

  • 11. [Incidence of haemolytic anaemia during combination therapy of chronic hepatitis C with interferon alpha-2b and ribavirin].
    Adamek A; Adamek J; Juszczyk J
    Pol Merkur Lekarski; 2004 Nov; 17(101):443-5. PubMed ID: 15754628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C.
    Bräu N
    J Viral Hepat; 2004 May; 11(3):191-7. PubMed ID: 15117320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
    Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
    J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 16. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT; Wasserman R; Bräu N; Hassanein TI; Bini EJ; Bowers PJ; Sulkowski MS
    Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.
    Alvarez D; Dieterich DT; Brau N; Moorehead L; Ball L; Sulkowski MS
    J Viral Hepat; 2006 Oct; 13(10):683-9. PubMed ID: 16970600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
    Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR
    Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection.
    Henry DH; Slim J; Lamarca A; Bowers P; Leitz G;
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):1-9. PubMed ID: 17263626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response.
    Hung CH; Lee CM; Lu SN; Wang JH; Chen CH; Hu TH; Kee KM; Chang KC; Tseng PL; Yen YH; Changchien CS
    Liver Int; 2006 Nov; 26(9):1079-86. PubMed ID: 17032408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.